Compare Amgen, Inc. (AMGN) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Financial Select Sector SPDR Fund — how do they compare? Amgen, Inc. trades at $414.85 (market cap $224.14B), while Financial Select Sector SPDR Fund trades at $57.73. The key difference: Amgen, Inc. pays a 2.43% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| AMGN | XLF | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | — |
52-Week High | $417.20 | $58.01 |
52-Week Low | $271.18 | $47.80 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
XLF trades at $57.88, up 0.12% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF recently crossed above its 200-day moving average, indicating positive momentum. Recent news highlights strong inflows into sector ETFs and potential opportunities from AI infrastructure financing.
The outlook for XLF is supported by technical strength and sector tailwinds, but overbought RSI levels suggest near-term caution. Key risks include interest rate sensitivity and market volatility. Analyst sentiment is generally positive, focusing on the financial sector's role in economic growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
